Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 323 participants.
Also called NCT01476475
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 323 participants
- Sponsor
- Registry
-
NCT01476475 -
2011-002090-36
-
- Other papers using this trial's data
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Chile, Czechia, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01476475. Randomized; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2017-02-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine /lixisenatide Fixed Ratio Combination
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Metformin (Background drug)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01476475- Content hash
f056cd93ab03f798a6147cdca1a392c67f5d9cf466492845b7c17e26e2f8ad76